Form 4: ClearPoint Neuro Director Acquires Shares in Lieu of Fees

Pascal E. R. Girin, a director of ClearPoint Neuro, Inc., acquired 1,333 shares of common stock on July 1, 2024, in payment of director fees.

Summary

• On July 1, 2024, Pascal E. R. Girin, a director of ClearPoint Neuro, Inc., acquired 1,333 shares of the company's common stock.
• The shares were issued as payment for director fees under the company's Non-Employee Director Compensation Plan.
• The price per share was $5.39, based on the closing price of ClearPoint Neuro's common stock on June 28, 2024.
• Following the transaction, Girin directly owns 73,530 shares of ClearPoint Neuro, Inc.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director taking shares in lieu of cash shows confidence in the company's future and helps conserve cash.

Positives

• The acquisition reflects the director's continued investment in the company.
• Using shares to pay director fees conserves the company's cash resources.

Industry Context

Directors receiving stock in lieu of cash compensation is a common practice, especially for smaller companies, to conserve cash and align director interests with shareholders.

Comparison to Industry Standards

• Stock compensation for board members is a common practice across the biotech and medical device industries.
• Companies like Medtronic and Stryker also use stock options and grants as part of their director compensation packages.
• The amount of stock granted to Girin appears to be within a reasonable range for a director of a company with ClearPoint Neuro's market capitalization.

Related Party Transactions

• The issuance of shares to Pascal E. R. Girin in payment of director fees is a related party transaction.

Stakeholder Impact

• Shareholders are indirectly impacted positively as the company conserves cash.
• The director's increased stake aligns his interests further with those of shareholders.

Key Dates